News MedicalAtorvastatin Reduces Major Cardiovascular Events but Misses Disability-Free Survival Goal

The STAREE trial evaluated whether statin therapy could support healthy longevity in adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia. In this double-blind randomized trial, 9,971 Australian participants received atorvastatin 40 mg daily or placebo and were followed for a median of 5.9 years. While atorvastatin produced a 30% reduction in major cardiovascular events, the intervention did not significantly improve the co-primary endpoint of disability-free survival, defined as survival without dementia or persistent physical disability. The findings provide long-sought randomized evidence supporting primary cardiovascular prevention in older adults while highlighting the distinction between event reduction and broader healthy-aging outcomes.

Clinical Considerations

• Major cardiovascular events occurred in 6.0% versus 8.3% of participants receiving atorvastatin versus placebo (HR 0.70; p<0.001).
• The cardiovascular endpoint included cardiovascular death, nonfatal myocardial infarction, stroke, or coronary revascularization.
• Disability-free survival did not significantly differ between groups (12.8% vs. 13.6%; HR 0.94; p=0.25).
• Participants represented an understudied population: adults aged 70 years or older without diagnosed cardiovascular disease, diabetes, or dementia.
• Muscle-, liver-, and diabetes-related adverse events were more frequent with atorvastatin, although serious adverse events remained uncommon.
• Serious adverse events occurred in 2.7% of participants in both groups, suggesting no major difference in severe safety outcomes.

Practice Applications

• Recognize that cardiovascular event reduction and disability-free survival represent distinct outcomes that may not move in parallel.
• Interpret the findings as strong randomized evidence supporting cardiovascular risk reduction in older adults without established cardiovascular disease.
• Discuss potential benefits and adverse effects with older patients considering statin therapy for primary prevention.
• Monitor for muscle, hepatic, and diabetes-related adverse effects when evaluating statin therapy in older populations.
• Review future guideline updates that may incorporate STAREE findings into primary prevention recommendations for healthy older adults.